Isomorphic Labs 在六個月內完成第二輪大型融資,集資 $5 billion
Isomorphic Labs raises $5 billion in its second mega-round within six months
Isomorphic Labs 集資 $5 billion,這是該公司六個月內第二輪十億美元級融資,由 Greenoaks 和 Sequoia Capital 共同領投,Andreessen Horowitz、Alphabet 及所有現有投資者亦有參與。
這輪融資不只支持 IsoDDE 平台研發,也用於推動藥物管線進入臨牀試驗,呈現公司的資金如何同時投向技術平台與藥物開發。
Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.
The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.
The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.
Deepmind's original AlphaFold team was disbanded in July 2026. Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely. Deepmind still shipped AlphaGenome 2 in early November 2026, which predicts how DNA variants affect gene activity in specific cell types.
AI News Without the Hype – Curated by Humans
Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.
來源:The Decoder · the-decoder.com